BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27154346)

  • 1. Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option.
    Wang M; Gao Z; Zhang Y; Pan L
    Appl Microbiol Biotechnol; 2016 Jul; 100(13):5691-701. PubMed ID: 27154346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria.
    Wells JM; Mercenier A
    Nat Rev Microbiol; 2008 May; 6(5):349-62. PubMed ID: 18345021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering lactococci and lactobacilli for human health.
    Bermúdez-Humarán LG; Aubry C; Motta JP; Deraison C; Steidler L; Vergnolle N; Chatel JM; Langella P
    Curr Opin Microbiol; 2013 Jun; 16(3):278-83. PubMed ID: 23850097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update.
    LeBlanc JG; Aubry C; Cortes-Perez NG; de Moreno de LeBlanc A; Vergnolle N; Langella P; Azevedo V; Chatel JM; Miyoshi A; Bermúdez-Humarán LG
    FEMS Microbiol Lett; 2013 Jul; 344(1):1-9. PubMed ID: 23600579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lactic acid bacteria--20 years exploring their potential as live vectors for mucosal vaccination.
    Wyszyńska A; Kobierecka P; Bardowski J; Jagusztyn-Krynicka EK
    Appl Microbiol Biotechnol; 2015 Apr; 99(7):2967-77. PubMed ID: 25750046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines.
    Bermúdez-Humarán LG; Kharrat P; Chatel JM; Langella P
    Microb Cell Fact; 2011 Aug; 10 Suppl 1(Suppl 1):S4. PubMed ID: 21995317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes.
    Cano-Garrido O; Seras-Franzoso J; Garcia-Fruitós E
    Microb Cell Fact; 2015 Sep; 14():137. PubMed ID: 26377321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lactic acid bacteria as oral delivery systems for biomolecules.
    Berlec A; Ravnikar M; Strukelj B
    Pharmazie; 2012 Nov; 67(11):891-8. PubMed ID: 23210237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advances in the use of lactic acid bacteria as mucosal delivery vectors of therapeutic molecules].
    Zeng Z
    Sheng Wu Gong Cheng Xue Bao; 2021 Jul; 37(7):2272-2282. PubMed ID: 34327894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant lactic acid bacteria as delivery vectors of heterologous antigens: the future of vaccination?
    Trombert A
    Benef Microbes; 2015; 6(3):313-24. PubMed ID: 25245573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lactic acid bacteria - promising vaccine vectors: possibilities, limitations, doubts.
    Szatraj K; Szczepankowska AK; Chmielewska-Jeznach M
    J Appl Microbiol; 2017 Aug; 123(2):325-339. PubMed ID: 28295939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal vaccination and therapy with genetically modified lactic acid bacteria.
    Wells J
    Annu Rev Food Sci Technol; 2011; 2():423-45. PubMed ID: 22129390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health.
    Levit R; Cortes-Perez NG; de Moreno de Leblanc A; Loiseau J; Aucouturier A; Langella P; LeBlanc JG; Bermúdez-Humarán LG
    Gut Microbes; 2022; 14(1):2110821. PubMed ID: 35960855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lactococcus lactis as a live vector: heterologous protein production and DNA delivery systems.
    Pontes DS; de Azevedo MS; Chatel JM; Langella P; Azevedo V; Miyoshi A
    Protein Expr Purif; 2011 Oct; 79(2):165-75. PubMed ID: 21704169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new lactobacilli in vivo expression system for the production and delivery of heterologous proteins at mucosal surfaces.
    Allain T; Mansour NM; Bahr MM; Martin R; Florent I; Langella P; Bermúdez-Humarán LG
    FEMS Microbiol Lett; 2016 Jul; 363(13):. PubMed ID: 27190148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria.
    Cortes-Perez NG; Lefèvre F; Corthier G; Adel-Patient K; Langella P; Bermúdez-Humarán LG
    Vaccine; 2007 Sep; 25(36):6581-8. PubMed ID: 17675182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Display of recombinant proteins at the surface of lactic acid bacteria: strategies and applications.
    Michon C; Langella P; Eijsink VG; Mathiesen G; Chatel JM
    Microb Cell Fact; 2016 May; 15():70. PubMed ID: 27142045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactic acid bacteria as live vaccines.
    Mercenier A; Müller-Alouf H; Grangette C
    Curr Issues Mol Biol; 2000 Jan; 2(1):17-25. PubMed ID: 11464916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of lactic acid bacteria as mucosal vaccines].
    Bermúdez-Humarán LG; Langella P
    Rev Francoph Lab; 2009 Dec; 2009(417):79-89. PubMed ID: 32518601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of vaccine delivery vehicles based on lactic acid bacteria.
    Tarahomjoo S
    Mol Biotechnol; 2012 Jun; 51(2):183-99. PubMed ID: 21901278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.